Key Takeaways
- The SCRIPT study tests regulated cannabis sales in Swiss pharmacies, focusing on quality counseling and consumer behavior.
- Interim results show that legal access does not increase cannabis consumption; in fact, it slightly decreased.
- Pharmacy staff provide personalized counseling, which shifts consumers toward lower-risk consumption methods.
- Unlike U.S. dispensaries, the SCRIPT model operates on a nonprofit basis with a strong emphasis on harm reduction.
- The study runs through 2029, aiming to inform future cannabis regulations in Switzerland.
For decades, the cannabis debate has split into two camps shouting past each other: one side warns that legal access breeds more use and more harm, the other insists prohibition causes more damage than the plant itself. Switzerland just ran an actual experiment instead of another argument.
The SCRIPT study, short for Safer Cannabis Research in Pharmacies randomized controlled Trial, is testing what happens when cannabis gets treated less like a vice to be taxed and more like a product that deserves proper counseling, quality control, and honest information. Nine pharmacies across three Swiss cities are selling regulated flower, resin, e-liquids and tinctures to 1,177 existing regular consumers, all under the supervision of trained pharmacy staff.
The interim results, which were recently released, offer one of the clearer real-world answers yet to a question that has fueled prohibition policy for generations: does legal access make people consume more? According to the study’s interim report, the answer is no. If anything, consumption ticked down slightly.
That finding alone is notable. But the more interesting story is what regulated access seems to be doing to how people consume, not just how much.
What Is the SCRIPT Study and How Does It Work?
SCRIPT is a joint project between the Universities of Bern and Lucerne, backed by the Swiss National Science Foundation and the Tobacco Prevention Fund. Launched in March 2024 and now approved to run through October 2029, the study operates on what researchers call a nonprofit model: sales cover operating costs without generating a profit motive to push volume.
Participants must already be regular cannabis consumers and adults living in the canton of Bern or the city of Lucerne. They’re randomly split into two groups, one that can buy products immediately and a delayed group that gains access six months later. This randomization gives researchers a genuine comparison point rather than relying on self-reported before-and-after data alone.
Products come from a single Swiss manufacturer, Pure Production AG, under strict quality testing and organic production standards, with THC capped at 20 percent by law. Five pharmacies operate in Bern, three in Lucerne and one in Biel.
What sets the model apart isn’t just legal access. It’s the counseling layer. Pharmacy staff are trained to walk participants through consumption options. Pharmacies also function as a touchpoint for questions about tobacco and alcohol use, according to the study’s own site.
What Did the Interim Results Actually Show?
According to the six-month interim report presented jointly by the social directorates of Bern, Biel and Lucerne, regulated access did not increase how often participants used cannabis. The report describes “ganz leichte Abwärtstendenzen,” or slight downward tendencies, in consumption frequency.
Lead researcher Reto Auer of the Bern Institute of Primary Health Care told reporters that the study also gathered evidence suggesting regulated pharmacy sales can encourage a shift toward potentially lower-risk consumption methods, according to Bern’s official press release. Seventy-one percent of participants said they passed along harm-reduction information they’d received at the pharmacy to people in their own social circles, extending the reach of that counseling well beyond the individual buyer.
Product breakdown adds context: 65 percent of sales were flower, followed by e-liquids at 21 percent. Pricing sits close to illicit-market rates but includes a simulated tax that helps fund the pharmacy counseling itself. Steady sales figures suggest participants accepted that modest markup as reasonable, though buyers under 25 reacted more negatively to higher prices than older participants.
The demographic makeup skews heavily male, at 78.1 percent, with the largest age bracket falling between 26 and 35.
Why Did Pharmacies Change How People Consume Cannabis?
The counseling piece appears to be doing real work. When pharmacy staff are trained to explain the health tradeoffs between smoking, vaporizing and oral consumption, and when that conversation happens every time someone walks in to buy, it creates a repeated nudge that a dispensary transaction or an illicit-market deal simply doesn’t offer.
Participants also cited factors beyond the counseling itself. Consistent product quality, clear labeling of ingredients and THC content, and the ability to buy without any contact with the illicit market all ranked as valued benefits in participant interviews, according to the interim results. One interview report noted that for many buyers, the open illicit market had simply stopped being relevant to their routine.
Pharmacy staff satisfaction was reportedly high as well, with staff highlighting positive interactions with the new customer base, though several requested more hands-on training around vaporizers and e-liquids specifically.
None of this happened by accident. It’s a byproduct of designing the sales environment around health outcomes instead of transaction volume.
How Does Switzerland’s Pharmacy Model Compare to U.S. Dispensaries?
U.S. dispensaries operate on a retail logic. Budtenders are helpful, often knowledgeable, and increasingly focused on customer experience, but the underlying business model rewards repeat purchases and larger basket sizes, not necessarily lower-risk consumption patterns.
Choose the Swiss pharmacy model if the policy goal is minimizing individual health harms alongside access. Choose something closer to the American dispensary structure if the priority is tax revenue generation and rapid market development. The two goals aren’t mutually exclusive, but they pull design decisions in different directions, and SCRIPT makes that tension visible.
Switzerland’s nonprofit pricing structure is the other major departure. Because sales revenue only covers costs rather than generating margin, there’s no built-in incentive to grow consumption. American dispensaries, operating in a for-profit and often heavily taxed environment, don’t have that same built-in restraint. It’s a structural difference, not a matter of one country’s operators being more or less ethical than the other’s.
What Can Germany and Other European Markets Learn from Switzerland?
Germany’s Cannabis Act, or Cannabisgesetz, took effect on April 1, 2024, making it the largest country to legalize recreational adult use for a general population. Germany’s system still leans heavily on pharmacies for medical cannabis, but its recreational framework has centered more on home cultivation and nonprofit cannabis clubs than pharmacy-based retail sales.
That’s a meaningfully different structure than Switzerland’s approach. Cannabis clubs put distribution in the hands of member associations rather than trained pharmacy staff providing individualized counseling at the point of sale. Both models reject a pure commercial retail approach, but only the Swiss pilot builds harm-reduction conversation directly into every transaction.
Other European pilot programs, including Switzerland’s own Zurich and St. Gallen trials run by Swiss Cannabis Research, are testing variations on this theme across different cities and populations. The common thread across these efforts is a rejection of the binary that has dominated American cannabis policy: legal commercial market versus continued prohibition. Europe is testing a wider menu of structural options in between.
What Does Harm-Reduction Design Mean for Cannabis Regulation Going Forward?
The strongest takeaway from SCRIPT isn’t that pharmacies beat dispensaries. It’s that regulated access can be deliberately engineered around reducing harm rather than simply replacing an illicit market with a taxed one.
That distinction matters for policymakers watching these pilots closely. Bern city councilwoman Ursina Anderegg noted that the results support the direction of Switzerland’s draft federal cannabis law, the Cannabisproduktegesetz (CanPG), which is currently under review in the Swiss parliament, according to the official press release. Biel’s director of social affairs and security, Natasha Pittet, pointed to a separate benefit: the study recorded no incidents involving resale to third parties or public consumption violations, suggesting the regulated framework holds up on the security side too.
SCRIPT now runs through October 2029, giving researchers years of additional data to refine what a health-first cannabis market can look like in practice. For an industry still arguing about tax rates and licensing caps, that’s a useful reminder that the point of legalization was never just about building a new retail category. It was about doing better than prohibition did.
Frequently Asked Questions
SCRIPT (Safer Cannabis Research in Pharmacies randomized controlled Trial) is a pilot study testing regulated, nonprofit cannabis sales through pharmacies in Bern, Lucerne and Biel. It combines legal access with trained staff counseling to study effects on consumption behavior and health.
No. Interim results found that regulated pharmacy access did not increase consumption frequency among the 1,177 study participants. Researchers observed slight downward tendencies instead.
The Swiss model runs on a nonprofit basis with mandatory harm-reduction counseling built into every sale, while U.S. dispensaries typically operate as for-profit retail businesses without a standardized counseling requirement.
The study offers flower, resin (hashish), e-liquids and tinctures, all produced by a single licensed Swiss manufacturer under strict quality and organic production standards, with THC capped at 20 percent.
The study was extended and now runs through October 2029, giving researchers additional years to study long-term consumption trends and inform Switzerland’s pending federal cannabis law, the CanPG.
